Drug Profile

SAB 301

Alternative Names: SAB-301

Latest Information Update: 25 Jun 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator SAB Biotherapeutics
Developer National Institutes of Health (USA)
Class Antibodies; Antivirals; Monoclonal antibodies; Polyclonal antibodies
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

No development reported Middle East respiratory syndrome coronavirus

Most Recent Events

20 Jun 2024 SAB Biotherapeutics is now called SAB BIO
28 Jun 2019 No recent reports of development identified for phase-I development in Middle-East-respiratory-syndrome-coronavirus(In volunteers) in USA (IV)
10 Jan 2018 SAB Biotherapeutics completes a phase I trial for Middle East respiratory syndrome coronavirus infection (In volunteers) in USA (IV)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com